Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories.
| Revenue (TTM) | $14.59B |
| Gross Profit (TTM) | $4.23B |
| EBITDA | $2.34B |
| Operating Margin | 10.90% |
| Return on Equity | 11.40% |
| Return on Assets | 5.48% |
| Revenue/Share (TTM) | $178.15 |
| Book Value | $108.96 |
| Price-to-Book | 3.38 |
| Price-to-Sales (TTM) | 2.02 |
| EV/Revenue | 2.493 |
| EV/EBITDA | 16.82 |
| Quarterly Earnings Growth (YoY) | 3.20% |
| Quarterly Revenue Growth (YoY) | 6.90% |
| Shares Outstanding | $81.20M |
| Float | $80.82M |
| % Insiders | 0.35% |
| % Institutions | 101.30% |
Volatility is currently expanding
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BURLINGTON, N.C., Nov. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10 at 8:45 a.m.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Labcorp Holdings raised guidance, triggering a sharp stock price rally. I view LH as a compelling long-term growth story, but current valuation is stretched. The price-earnings ratio approaching 20 exceeds my preferred range for LH's fundamentals.
Labcorp Holdings Inc. (LH) Q3 2026 Earnings Call Transcript
Labcorp NYSE: LH reported third-quarter 2026 revenue growth, margin expansion and double-digit adjusted earnings-per-share growth, prompting the laboratory services company to raise the midpoint of its full-year revenue and earnings outlook.
Labcorp shares rise as Q3 earnings and revenues beat estimates, both segments deliver growth, margins expand and the company raises its 2026 financial outlook.
WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer screening.
Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, patient service center, and at-home settings Through a network serving more than 850,000 physicians and healthcare providers and more than 2,200 patient service centers, Labcorp is helping expand access to cervical cancer screening nationwide First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping MILFORD, Mass. and BURLINGTON, N.C.
Investors interested in Medical Services stocks are likely familiar with Labcorp Holdings (LH) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LH and any ticker you trade — then tracks every position and per-strategy win rate.
